Epstein-Barr virus (EBV) is carried by more than 95% of adults as a largely asymptomatic infection. Primary infection with EBV normally occurs through salivary exchange in the oropharynx, and this is believed to result in virus replication in stratified squamous epithelial cells and in the subsequent infection of trafficking B lymphocytes. Following primary infection, whether symptomatic or silent, the virus persists in the healthy host for life through mechanisms that are not fully understood. Although some form of latent infection in epithelial cells represents one possible strategy for virus persistence, most recent studies favor the concept of virus carriage in the lymphoid compartment via the long-term survival of non-productively infected B cells (15, 52) . Accordingly, there is renewed interest in the different types of virus-cell interactions that can occur in EBV-infected B lymphocytes, and in this context much can be learned from in vitro models.
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The best-characterized EBV-B cell interaction is that shown by lymphoblastoid cell lines (LCLs) established following experimental infection of resting B cells in vitro. These growth-transformed cells are to a large extent nonpermissive for virus replication and express just nine viral proteins (reviewed in reference 23) , including six nuclear antigens (EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, and EBNA-LP) and three membrane proteins (LMP1, LMP2A, and LMP2B). In LCLs, all six EBNA mRNAs are differentially spliced from long transcripts initiated either from the Cp * Corresponding author. t Present address: Institute of Virology and Environmental Microbiology, Mansfield Rd., Oxford OX1 3SR, United Kingdom.
promoter or from the adjacent Wp promoter at the "leftward" end of the viral genome (42, 51) , while the LMP mRNAs are transcriptionally controlled by promoters at the "rightward" end of the genome that are responsive to transactivation by EBNA2 (10, 24, 50, 56) . Coordinate expression of the EBNAs and LMPs in experimentally infected B cells leads not only to growth transformation but also to a dramatic change in the cellular phenotype, with upregulation of several B-cell surface activation markers (i.e., CD23, CD30, CD39, and CD70) and adhesion molecules (LFA-1, ICAM-1, and LFA-3) as well as of the cellular oncogene bcl-2. Gene transfection studies have attributed certain facets of the above phenotypic change to the effects of individual latent proteins. Thus, EBNA2 and EBNA3c can upregulate expression of some of the cellular activation antigens, while LMP1 has multiple effects, including upregulation of the cellular adhesion molecules, of CD23, and of the bcl-2 oncogene (18, (47) (48) (49) .
A second form of latent infection in B cells is exemplified by certain EBV-positive Burkitt's lymphoma (BL) cell lines which express only EBNA1 and no other viral proteins (17, 39) . At the transcriptional level, these cells show expression of EBNA1 mRNA initiated exclusively from an Fp promoter which is located about 50 kb downstream of the Cp and Wp promoters used in LCLs (42) . These BL lines are also phenotypically distinct from LCLs since they display undetectable or very low levels of the B-cell activation antigens and cellular adhesion molecules that are abundantly expressed in LCLs and instead express certain other markers (e.g., CD10 and CD77) that are not seen on LCLs (16, 34 (34) . However, many established BL tumor cell lines progress upon serial passage in vitro to display a group III cell surface phenotype, which is similar to that displayed by normal LCLs. This switch from a group I to a group III cellular phenotype is associated with induced expression of the full range of nine latent viral proteins that are expressed in LCLs (39) . At the transcriptional level, the activation of latent gene expression is reflected by a switch from Fp promoter usage to Cp and/or Wp promoter usage for initiation of EBNA transcripts (42) .
Another interesting feature of the above phenotypic drift is that while all group I BL lines generally display a tightly latent EBV infection, group III lines often contain a small proportion of cells in the lytic cycle, as do LCLs (17) . This suggested that the natural route from EBNA1+ latency into the lytic cycle in B cells may involve, as a necessary intermediate step, transient acquisition of full virus latent gene expression and an LCL-like cellular phenotype. We began the present series of experiments specifically to examine this question by following the response of group I BL cell lines to reported inducers of the lytic cycle. In so doing, we identified three distinct pathways of EBV gene activation from EBNA1+ latency.
MATERIALS AND METHODS
Cell lines. Seven of the BL lines used in this work had been well characterized previously and were selected because they were known to display a group I cell surface phenotype and to express EBNA1 in the absence of the other latent viral proteins (17, 18, 39 (coordinates 380 to 361; sequence CATGTTAGGCAAATT GCAAA) and a common exon 2 probe (coordinates 62 to 81; sequence ATCCAGTATGCCTGCCTGTA) were used. The 5' primer used to detect the LMP2A transcripts was from the unique coding exon 1 (coordinates 166874 to 166893; sequence ATGACTCATCTCAACACATA), while the 5' primer used to detect the LMP2B transcript was from the unique noncoding exon 1 (coordinates 169819 to 169838; sequence CAGTGTAATCTGCACAAAGA).
RESULTS
Responsiveness of group I BL cell lines to anti-Ig and to TPA. Preliminary experiments were performed with the Akata-BL line as a control line known to be sensitive to two inducers of the lytic cycle, anti-Ig and TPA (8, 45 LCL transformed with the same BL virus isolate and expressing the full spectrum of latent proteins.
The results in Fig. 1 show that Akata-BL was activated into the lytic cycle very efficiently by anti-Ig and to a lesser extent by TPA (Fig. 1C) , a result consistent with published data (8) . In addition, it was also noted that activation via anti-Ig induced expression of LMP1 to a level comparable to that expressed in the corresponding LCL, whereas EBNA2 was not induced (Fig. 1B) : in this particular experiment, TPA induced barely detectable levels of LMP1, but in other experiments in which activation of the lytic cycle was more efficient, the coinduction of LMP1 was more marked (data not shown). Similar results were obtained with the Eli-BL line, except that here the treatments with anti-Ig and TPA both induced lytic cycle antigens with similar efficiency (Fig.  1C) . As with the Akata-BL line, both treatments of Eli-BL also induced the expression of LMP1 but not of EBNA2 (Fig. 1B) . Three lines (Mutu-BL, BL37, and Wan-BL) were activated with varying efficiency by TPA to express lytic cycle antigens and LMP1 but were unresponsive to anti-Ig. This pattern of results is illustrated by the Wan-BL line in Fig. 1 . Another three lines (WW2-BL, Odhi-BL, and Chep-BL) were poorly responsive both to TPA and to anti-Ig, whether assessed by lytic cycle induction or by LMP1 expression (see Chep-BL line, Fig. 1 ).
In responsive group I BL cell lines, therefore, both types of treatment activated not only the EBV lytic cycle but also the expression of a latent viral protein, LMP1. We chose to investigate this phenomenon in more detail by concentrating on the induction of the Akata-BL and Eli-BL lines via anti-Ig. This choice was made because, compared with that of TPA, the effect of anti-Ig is rapid and synchronous. Furthermore Fig. 2 . Expression of the immediate-early protein BZLF1 was detected within 2 to 5 h postactivation (Fig. 2B) , followed by expression of a full-size LMP1 protein by 7 to 9 h (Fig. 2C) . In this particular experiment, a smaller LMP1 protein was also detected several hours after the full-size LMP1 was induced (Fig. 2C) , and it was tentatively designated truncated LMP1 (Tr-LMP1) because it may have initiated from an internal methionine codon in the LMP1 gene, as reported for TPAinduced B95.8 LCL cells (20) . In the present work, the full-length LMP1 protein was consistently induced, while the Tr-LMP1 was not always detected.
Immunofluorescence analysis of Akata-BL at the singlecell level showed that induction of LMP1 was confined to cells which had entered the lytic cycle. Cell smears were stained with monoclonal antibodies specific for the immediate-early BZLF1 protein, the EA(D) product of the BMRF1 gene, the VCA product of the BcLF1 gene, and the LMP1 and EBNA2 latent proteins. Representative results obtained in one of several experiments are illustrated in Fig. 3 . Between 2 and 9 h after the addition of anti-IgG, there was a sequential induction of the BZLF1, EA, LMP1, and VCA proteins (Fig. 3A) . Dichromatic staining for LMP1 and BZLF1 at 9 h postinduction showed that the LMP1 protein was expressed exclusively in the BZLF1+ (i.e., lytic cycle) cell population (Fig. 3B) ; these LMP+ BZLF1+ cells did not express EBNA2 (Fig. 3C) . LMP1 was therefore a genuine component of the lytic cycle, and its expression was independent of EBNA2. This first response pathway was also observed in anti-IgM-treated Eli-BL cells (see below).
In order to confirm that the full-size LMP1 protein observed above was indeed the product of latent LMP1 transcripts, total RNA preparations were analyzed for the presence of specific mRNA by reverse transcription and PCR amplification. The 2.8-kb latent LMP1 transcript that is abundantly expressed in latently infected LCLs from the EDL1 promoter (20) was reverse-transcribed with a 3' primer which spanned the exon 3-exon 2 splice junction, and PCR amplification was carried out after the addition of a 5' primer from exon 1. Note that this combination of primers does not detect the unspliced mRNA transcript which is driven from the EDLla promoter in TPA-induced B95.8 cells and which is thought to encode the Tr-LMP1 protein (20) . These primers amplified a 381-bp reverse-transcribed product, as expected, in the three LCLs tested (Fig. 4A ). There was a barely detectable amplification of this LMP1 product in the control Akata-BL line itself, but following induction of these cells for 24 h with anti-Ig, a 381-bp product was reproducibly obtained at a level comparable to that obtained with LCLs (Fig. 4A) .
It has been reported that LMP2 is usually coexpressed with LMP1 in latent infection (14) and that its expression can be elevated by TPA (26 and to BZLF1 at 9 h postactivation; LMP1 expression was detected by using the S12 monoclonal antibody and a rhodamine-conjugated anti-mouse IgG2a second-step antibody, while BZLF1 expression was detected by using the BZ1 monoclonal antibody and an FITCconjugated anti-mouse IgGl second step. (C) Expression of LMP1 (detected with S12 and anti-IgG2a) in the absence of EBNA2 (assayed with PE2 and anti-IgGl) at 9 h postactivation. was carried out with a 3' primer from the exon 3 common to both LMP2A and LMP2B mRNAs, and the products were amplified after the addition of a 5' primer from the unique first exon of either the LMP2A or the LMP2B mRNA. Specific products of 280 kb (LMP2A) or 324 kb (LMP2B) were detected by Southern blotting with a probe from the common exon 2. These combinations of primers and probes revealed that both LMP2A and LMP2B transcripts were indeed induced in Akata-BL cells following activation with anti-Ig (Fig. 4B and C) , exactly paralleling the observations on LMP1 transcription. Pathway 2: switch to an LCL-like (EBNA2' LMP+) form of latency. Extension of the time course over which anti-Ig activation of Akata-BL cells was followed revealed the existence of a second, delayed response pathway. As shown in Fig. 5A , maximal expression of lytic cycle antigens was obtained by 12 to 24 h postactivation, and after a further 24 h, a small subpopulation of EBNA2+ cells was detected.
Dichromatic staining revealed that the EBNA2+ cells present by 48 h did not coexpress either LMP1 (Fig. 5B) or the late lytic cycle antigen gp340 (Fig. SC) and were therefore clearly distinct from those cells previously activated into the lytic cycle. However, by 72 h, 20 to 30%o of the EBNA2+ cells had activated LMP1 expression (Fig. SD) , and a small minority of these EBNA2+ LMP1+ cells expressed lytic cycle antigens (data not shown), just as would be expected of cells moving into an LCL-like form of infection. This second response pathway was also observed with anti-IgM-treated Eli-BL cells (see below).
Pathway 3: switch to a novel (EBNA2-LMP1+) form of latency. Activation of the Eli-BL line by treatment with anti-IgM was followed as for the Akata-BL line, and here the results revealed three different response pathways. Compared with Akata-BL, a smaller proportion of the Eli-BL cells were activated directly into the lytic cycle, and the kinetics of this response were slightly slower. Thus, the first BZLF1+ cells appeared at 9 to 12 h (Fig. 6A) , at which time these cells were LMP1- (Fig. 6B ). Just as with the Akata-BL, however, progression of these cells through the lytic cycle was accompanied by the induction of LMP1 as a lytic cycle antigen, so that by 24 h all the BZLF1+ cells coexpressed LMP1 (Fig. 6C ). Delayed induction of EBNA2 was again observed by 48 h in a small distinct subpopulation of cells (Fig. 6A) was the accumulation between 12 and 48 h postactivation of large numbers of LMP1 + cells which were neither in the lytic cycle (Fig. 6A, B , and C) nor expressing EBNA2 (Fig. 6A  and D) . This third response pathway was a dominant feature of the Eli-BL response, whether activated by anti-Ig or by TPA, but was never observed in activated Akata-BL cultures. Analysis of mRNA from the Eli-BL cells at 24 h postactivation showed that, as with the induced Akata-BL cells (see Fig. 4 ), LMP1 was being expressed from the characteristically spliced latent LMP1 mRNA and that the LMP2A and LMP2B transcripts were also coinduced with LMP1 (data not shown). However, because two distinct LMP1+ populations were present in the Eli-BL cultures at this time, it was not possible to ascertain whether LMP2A and LMP2B were expressed in both or just one of these populations.
Phenotypic effects of LMP1 expressed in different response pathways. In a B-lymphocyte environment, LMP1 can mediate a number of changes in cellular phenotype. These include upregulation of cellular adhesion molecules such as LFA-3 (47), of some but not all cell surface activation antigens (e.g., CD23 but not CD39 [47, 49] ), and of the cellular oncogene bcl-2 (18). We therefore investigated whether such changes were induced by LMP1 when expressed either in the lytic cycle (the dominant response pathway in Akata-BL) or in the EBNA2-LMP1+ form of latency (the dominant response pathway in Eli-BL). Anti-Igmediated activation of about 20% of Akata-BL cells into the lytic cycle did not cause upregulation of any of the above cell surface markers (Fig. 7A) or of the bcl-2 oncogene (data not shown). In contrast, anti-Ig-induced Eli-BL contained a subpopulation cells staining for LFA-3 at an intensity similar to that observed on LCLs and for CD23 at a lower intensity, while there was no induction of CD39 (Fig. 7A) . Dichromatic staining for LMP1 and LFA-3 and for LMP1 and CD23 confirmed that the observed surface changes occurred in LMP1+ cells (data not shown). Interestingly, these cells did not show demonstrable activation of bcl-2 expression (Fig.  7B ).
DISCUSSION
The variety of possible EBV-B cell interactions is well illustrated by the present in vitro models. These different forms of infection, and the observed transitions between them, are summarized in Fig. 8 (12, 44) , irreversibly initiating the cascade of lytic cycle gene expression (11, 22 (42, 51) . Furthermore, these EBNA2+ cells subsequently progressed to express LMP1, with only a minority then entering the lytic cycle (Fig. 5) . Together, these observations strongly suggest that the EBNA2+ subpopulation is in the process of switching from Lat I to a Lat III form of infection, a route already observed in previous studies monitoring spontaneous progression of BL lines from a group I to a group III cellular phenotype on serial passage (17, 34, 39) .
Perhaps the most interesting response pathway identified in the present work is that leading from Lat I to a form of latency, Lat II, not hitherto recognized in B cells. To date, the only examples of this EBNA1+ LMP+ form of infection have involved EBV-associated tumors of non-B-cell origin, namely, nasopharyngeal carcinoma (9, 54) and Hodgkin's disease (30) . Here, we show that under certain circumstances B lymphocytes can support a Lat II form of infection and that, at least in this in vitro system, LMP can be expressed as a latent antigen independently of EBNA2-mediated transactivation (10, 50) . Since LMP1 has the potential to alter several facets of the B-cell phenotype (18, 47, 49) , we questioned to what extent such LMP1-associated changes accompanied the switch from a Lat I to a Lat II form of infection. Interestingly, some of the expected changes, e.g., upregulation of LFA-3 and CD23, were observed, whereas another change, upregulation of bcl-2, was not (Fig. 7) . In contrast, the switch from Lat I into the lytic cycle, although also associated with induction of LMP1 expression, did not alter any of the above phenotypic properties. We interpret this latter observation to be a consequence of the fact that entry of herpesvirus-infected cells into the lytic cycle results in rapid inhibition of cellular metabolism.
We suggest that all three forms of latency here 
